Osteosarcoma Stem Cell Therapy Development

Osteosarcoma is the most common type of bone malignancy that develops from mesenchymal cell lines and mainly affects adolescents and young adults. The current long-term survival outlook for osteosarcoma is not good, and therefore, there is a need to optimize current therapeutic strategies and develop new approaches to treat osteosarcoma. CD BioSciences has launched a development service for osteosarcoma stem cell therapies, dedicated to advancing the treatment of this disease.

Overview of Osteosarcoma

Osteosarcoma frequently appears in bones that are growing quickly. It most frequently develops in the medullary cavity of the metaphyseal region of long bones and penetrates the cortex of the bone to affect the surrounding soft tissues. Around the penetrating tumor, a pseudo capsule develops. Osteosarcoma has been linked to physical, chemical, and biological agents that are carcinogens. The roles of ionizing radiation and ultraviolet light are the most obvious. Numerous genetic and chromosomal syndromes have also been linked to osteosarcoma. Patients with the following syndromes—Bloom syndrome, Rothmund-Thompson syndrome, Werner syndrome, Li-Fraumeni syndrome, and hereditary retinoblastoma—have reportedly developed osteosarcoma recently.

Osteosarcoma New Marker PTHR1

The parathyroid master cells secrete a polypeptide hormone known as parathyroid hormone (PTH). By influencing osteoblasts and osteoclasts via the cyclic adenosine monophosphate (cAMP) and phospholipase C pathways, it regulates blood calcium levels. The parathyroid hormone receptor 1 (PTHR1) is a member of the G protein-coupled cell membrane receptor family, which is widespread and significant in canine and rat osteosarcoma. PTH and PTH-related peptide (PTHrP), which are primarily expressed in bone, kidney, and cartilage, are both bound by PTHR1.

PTHR1 is associated with osteosarcoma development. (Chaonan Sun. et al. 2021)

Regulatory Mechanism of PTHR1 in Osteosarcoma

PTHR1 is known to control the malignant progression of osteosarcoma through specific mechanisms involving matrix metalloproteinases, non-coding RNA, and genetic foci, according to numerous sources.

• Matrix Metalloproteinases and Extracellular Matrix Regulation by PTHR1
  In osteosarcoma cells cultured with -alanine, results have been shown for the attenuation of PTHR1 mRNA and protein expression, suggesting a favorable relationship with tumor invasion and metastasis. Tissue inhibitors of metalloproteinases (TIMP)-1 and TIMP-2 were highly expressed in them, whereas MMP-2 and MMP-9 mRNA expression levels were significantly downregulated.
• Non-coding RNA and Key Genes Implicated in PTHR1 Regulation
  Recent research suggests that PTHR1 may have a significant impact on osteosarcoma progression by activating the miRNA genes miR-124-3p-AR-Tgfb1i1, miR-a-3p-PPARG-27 Abca1, and miR-103/590-3p-AXIN2. Further bioinformatics research revealed that PTHR1 may have potential targets in osteosarcoma, including NR4A2, ZFPM2, RHOC, LEF1, and HAS2.

Our Services

CD BioSciences offers osteosarcoma stem cell therapy development services. The current 5-year survival rate for patients with osteosarcoma treated only by surgery is very low. Therefore, there is an urgent need to explore the pathogenesis of osteosarcoma and identify potential therapeutic targets. Based on our professional laboratory team, we can contribute to the development of stem cell therapy for osteosarcoma.

As a pioneer in biotechnology, CD BioSciences has grown into one of the largest independent biotechnology companies in the world. CD BioSciences is committed to providing professional and efficient service to our customers around the world. If you are interested in our service, please contact us.

Reference

1. Chaonan Sun. et al. (2021). PTHR1 in osteosarcoma: Specific molecular mechanisms and comprehensive functional perspective. J Cell Mol Med. 25(7):3175-3181.